-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Ascendis Pharma, Raises Price Target to $256

Benzinga·12/11/2025 13:24:28
語音播報
Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $254 to $256.